Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | GCK | P35557 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16491623 | 0.80 | HTT (0.59) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL2337555 | 0.78 | GCK (0.76) | GRM5GCKKMT2ARAB9A | |
| SCHEMBL3943486 | 0.78 | L3MBTL1 (0.51) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL14647654 | 0.78 | GRM5 (0.60) | GRM5GCKMAPTL3MBTL1MAPK1 | |
| SCHEMBL16415760 | 0.78 | MEN1 (0.52) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL11067263 | 0.78 | LTA4H (0.58) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL21769171 | 0.76 | NUDT1 (0.51) | NUDT1 | |
| SCHEMBL4502335 | 0.75 | MAPT (0.49) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL12226851 | 0.75 | L3MBTL1 (0.49) | GRM5MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL3869852 | 0.75 | L3MBTL1 (0.49) | GRM5MAPTL3MBTL1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | GRM5 1261/4885GCK 1106/4885MAPT 4820/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | GRM5 785/4885GCK 1095/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.